How does type 2 diabetes affect beta-cell function over time?

T2DM causes progressive beta-cell dysfunction through multiple mechanisms: chronic exposure to elevated glucose (glucotoxicity), elevated free fatty acids (lipotoxicity), inflammatory cytokines, and oxidative stress all impair insulin gene expression and secretory machinery. The UKPDS documented this as an approximately 4% annual decline in HOMA-β. By 10–15 years of T2DM, most patients have less than 20% of normal beta-cell function, necessitating insulin replacement.

Can beta cells recover or regenerate?

There is evidence that some functional recovery is possible when the metabolic burden is reduced. Bariatric surgery (particularly Roux-en-Y gastric bypass) can produce rapid normalization of beta-cell function within days, before significant weight loss — thought to be related to changes in GLP-1, GIP, and gut hormone secretion. Significant weight loss and GLP-1 agonist therapy also appear to improve HOMA-β. However, once significant beta-cell mass is lost (from autoimmune or prolonged glucotoxic destruction), full structural recovery is not achievable.

What does HOMA-Beta show in prediabetes?

In prediabetes (fasting glucose 100–125 mg/dL or HbA1c 5.7–6.4%), HOMA-β may be elevated (reflecting compensatory hypersecretion in response to insulin resistance) or beginning to decline. Early prediabetes with insulin resistance typically shows high HOMA-IR and elevated HOMA-β. Later prediabetes transitioning toward T2DM shows declining HOMA-β as secretory capacity fails to keep up with the insulin resistance burden — this is the tipping point where blood glucose starts rising.

Does metformin affect HOMA-Beta?

Metformin's primary mechanism is reducing hepatic glucose production, which lowers fasting glucose. Lower fasting glucose reduces glucotoxicity on beta cells, allowing some recovery of insulin secretion — this is reflected as a modest increase in HOMA-β with metformin treatment. However, metformin does not directly stimulate insulin secretion (unlike sulfonylureas) and does not have the direct beta-cell trophic effects proposed for GLP-1 agonists. Its effect on HOMA-β is modest and primarily mediated through glucose lowering.

Can HOMA-Beta be used in insulin resistance without diabetes?

Yes — and this is when HOMA-β shows one of its most informative patterns. In metabolic syndrome or insulin-resistant obese individuals with normal glucose, HOMA-β is often elevated above 100% (sometimes 150–200%), reflecting the pancreas working overtime to compensate for peripheral insulin resistance. This compensatory hypersecretion maintains normal glucose at the cost of hyperinsulinemia. Tracking HOMA-β decline over time in this population identifies those transitioning toward beta-cell decompensation and T2DM.

Online Medical Tools — HOMA-Beta

Printed on 9/2/2026

For informational purposes only. This is not medical advice.

Endocrinology

HOMA-Beta

HOMA-Beta (HOMA-%B) estimates pancreatic beta-cell function from fasting insulin and fasting glucose. It is often interpreted together with HOMA-IR and other glycemic markers to understand insulin secretion relative to insulin resistance.

Formula: HOMA-Beta = (360 x Fasting Insulin [uIU/mL]) / (Fasting Glucose [mg/dL] - 63)

Fasting Glucose

mg/dL

Fasting Insulin

uIU/mL

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Enter fasting insulin and glucose

Input fasting serum insulin (mcU/mL) and fasting plasma glucose (mg/dL), drawn after an 8–12 hour fast. The mg/dL glucose value is used directly. If your lab reports glucose in mmol/L, multiply by 18.0 to convert to mg/dL before entering. Glucose values below 64 mg/dL (3.6 mmol/L) cannot be used because the denominator of the formula approaches zero and the result becomes mathematically unreliable.

Calculator applies the HOMA-β formula

The tool applies HOMA-β = (360 × fasting insulin [mcU/mL]) / (fasting glucose [mg/dL] − 63), which is the mg/dL adaptation of the original Matthews et al. formula. This equation models basal beta-cell insulin secretion relative to the glucose stimulus under fasting steady-state conditions. The constant 360 comes from the original model's 20 × 18 conversion (mmol/L to mg/dL).

Interpret the result as a percentage of normal function

HOMA-β is expressed as a percentage where 100% represents the estimated beta-cell function of a healthy non-diabetic adult. Values of 80–120% are considered normal. Values below 80% suggest beta-cell decline; below 40% is consistent with significant secretory loss, typical of established T2DM at diagnosis. Values above 120% can reflect compensatory hypersecretion in early insulin resistance before glucose control deteriorates.

Who Uses the HOMA-Beta

Monitoring T2DM Beta-Cell Decline Over Time

Diabetologists, endocrinologists

The UKPDS demonstrated that T2DM patients have already lost approximately 50% of their beta-cell function by the time of diagnosis, and function continues to decline ~4% per year thereafter. Serial HOMA-β measurements over months and years document this progressive decline, helping guide the timing of therapy intensification (adding GLP-1 agonist, SGLT2 inhibitor, or insulin).

LADA Differentiation from T2DM

Endocrinologists, diabetologists

Latent Autoimmune Diabetes in Adults (LADA) is often misclassified as T2DM. LADA patients characteristically have low HOMA-β combined with positive anti-GAD antibodies (anti-glutamic acid decarboxylase). A HOMA-β below 25–30% in a patient thought to have T2DM should prompt testing for GAD antibodies to rule out LADA and guide appropriate treatment (insulin rather than sulphonylureas).

Assessing GLP-1 Agonist Beta-Cell Effects

Endocrinologists, clinical pharmacologists

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) are thought to exert beta-cell protective and possibly regenerative effects beyond glucose lowering. Serial HOMA-β monitoring before and during GLP-1 therapy provides objective evidence of whether beta-cell secretory function improves with treatment, informing therapy continuation decisions.

Predicting Insulin Requirement in T2DM

Primary care, internists, diabetologists

Very low HOMA-β (below 25–30%) in a T2DM patient is associated with near-complete beta-cell failure and predicts the need for insulin therapy. When oral agents are failing and HOMA-β is very low, this supports early insulin initiation rather than continued escalation of oral diabetes medications that depend on some residual beta-cell function (especially sulfonylureas).

New-Onset Diabetes Classification Research

Clinical researchers, diabetes investigators

Combination of HOMA-β with HOMA-IR creates a two-axis metabolic phenotype for new-onset diabetes: high HOMA-IR / normal HOMA-β (predominant insulin resistance), normal HOMA-IR / low HOMA-β (predominant secretory failure), or mixed. This phenotypic classification is used in research to identify patient subgroups most likely to respond to specific treatment approaches.

Pro Tips

The HOMA-β formula has a known mathematical limit

HOMA-β using the mg/dL formula becomes unreliable when fasting glucose exceeds approximately 450 mg/dL (equivalent to 25 mmol/L in the original formula), because the denominator grows proportionally with glucose, compressing the result. In severe hyperglycemia, HOMA-β underestimates true beta-cell function. Interpret with caution in patients with glucose above 300–350 mg/dL.

T2DM patients have lost ~50% of beta-cell function by diagnosis

The landmark UKPDS study demonstrated that at the time of T2DM diagnosis, patients have already lost approximately 50% of their beta-cell secretory capacity. This loss begins years before diagnosis during the prediabetes phase. HOMA-β typically falls from ~100% in healthy adults to 40–60% at T2DM diagnosis and continues declining ~4% per year thereafter.

Combine HOMA-β with HOMA-IR for full insulin axis picture

HOMA-β and HOMA-IR together characterize both sides of the insulin axis: secretion (HOMA-β) and action (HOMA-IR). A patient with high HOMA-IR but normal HOMA-β has compensated insulin resistance (early metabolic syndrome). A patient with low HOMA-β and normal HOMA-IR has primarily secretory failure (LADA, late T2DM). Both together provide a more complete metabolic phenotype than either alone.

GLP-1 agonists appear to improve HOMA-β over time

Multiple clinical trials of semaglutide and liraglutide have demonstrated increases in HOMA-β over 6–24 months of treatment, suggesting these agents preserve or restore some beta-cell secretory capacity. The mechanism may involve reduction in glucotoxicity, lipotoxicity, and direct beta-cell trophic effects mediated by GLP-1 receptors on islet cells.

LADA patients have low HOMA-β and positive anti-GAD antibodies

LADA accounts for 5–10% of patients initially diagnosed with T2DM. These patients characteristically have HOMA-β below 25–30% with positive anti-GAD antibodies, despite an apparently T2DM clinical presentation. Low HOMA-β in a lean-to-normal BMI patient with poor response to oral agents should always prompt anti-GAD antibody testing.

Early insulin resistance shows paradoxically elevated HOMA-β

In early insulin resistance (high HOMA-IR) with normal glucose, HOMA-β is often elevated above 100% — reflecting compensatory hypersecretion by a stressed but functional pancreas. This should not be interpreted as 'good' — it represents the overworked pancreas response to insulin resistance that precedes eventual beta-cell exhaustion and T2DM development.

Different ethnic groups have different baseline beta-cell capacities

East Asian populations have been shown to have lower beta-cell secretory capacity and lower HOMA-β at baseline compared to European populations at similar BMI and glucose levels. This explains why Asian individuals develop T2DM at lower BMI thresholds. Population-appropriate reference ranges should be used when available, particularly for Asian patient populations.

Exogenous insulin users cannot be assessed

HOMA-β requires endogenous insulin measurement. Patients already receiving insulin therapy (for T1DM or advanced T2DM) cannot be assessed because the assay cannot separate endogenous from exogenous insulin, and injected insulin creates artifactually elevated insulin readings. Only patients on oral medications or no diabetes medications can be evaluated.

Serial measurements are more informative than single values

A single HOMA-β measurement provides a snapshot; serial measurements over 6–12 month intervals during T2DM management create a trend that reveals disease progression rate. Stable or improving HOMA-β on a GLP-1 agonist versus declining HOMA-β on metformin alone can objectively guide therapy optimization decisions.

Common Questions About Your Results

The HOMA-β formula uses (glucose - 63) as the denominator (in the mg/dL version). While this doesn't cause a division-by-zero problem at typical glucose levels, very high glucose values above 300–450 mg/dL produce a large denominator that compresses the HOMA-β result, causing the formula to underestimate true beta-cell function. In severe hyperglycemia, glucotoxicity itself suppresses beta-cell function reversibly, so both the formula and the true beta-cell function are impaired — making interpretation complex. The original formula was validated for fasting glucose below approximately 25 mmol/L (450 mg/dL).

Not reliably on its own. Both late-stage T2DM and T1DM can produce very low HOMA-β values. The critical differentiator is anti-GAD antibody testing (positive in T1DM and LADA, negative in T2DM) combined with clinical context: age of onset, BMI, rate of metabolic deterioration, and C-peptide levels. Very low HOMA-β with positive anti-GAD antibodies indicates autoimmune diabetes (T1DM or LADA), while very low HOMA-β with negative antibodies suggests end-stage T2DM.

This is a feature of the model, not a flaw: in early insulin resistance (high HOMA-IR, normal glucose), the pancreas compensates by secreting more insulin. This hyperinsulinemia raises both the numerator of HOMA-β (fasting insulin) and the denominator (fasting glucose remains near-normal). The net result is HOMA-β often elevated above 100% during the compensated hyperinsulinemia phase. This elevated HOMA-β actually signals the stressed-but-working pancreas and predicts future beta-cell failure if insulin resistance is not addressed.

Yes, in different directions. Metformin slightly increases HOMA-β by reducing glucotoxicity. GLP-1 receptor agonists increase HOMA-β more significantly by improving beta-cell function directly. Sulfonylureas increase HOMA-β acutely by directly stimulating insulin secretion — but this reflects pharmacological stimulation rather than true functional reserve. Exogenous insulin cannot be assessed at all (assay cannot distinguish endogenous insulin). When using HOMA-β to assess true secretory reserve, results should be interpreted in context of current medications.

Evidence-Based Methodology

HOMA-β was introduced by Matthews et al. (Diabetologia 1985) alongside HOMA-IR as part of the Homeostatic Model Assessment framework. It estimates relative beta-cell secretion under fasting conditions. The UKPDS (United Kingdom Prospective Diabetes Study) demonstrated progressive beta-cell decline in T2DM patients, establishing the clinical context for HOMA-β monitoring. HOMA-β was validated against intravenous glucose tolerance test (IVGTT)-based measurements of first-phase insulin secretion (Turner et al., Diabetologia 1979). The GLP-1 agonist effects on HOMA-β are documented in semaglutide and liraglutide trials (SUSTAIN and LEADER trials, N Engl J Med 2016–2017).

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

HOMA-Beta estimates beta-cell function; lower values may suggest reduced insulin secretory reserve, while higher values can reflect compensatory hyperinsulinemia.

When to Use This Tool

Use HOMA-Beta when evaluating fasting insulin secretion patterns in prediabetes and type 2 diabetes risk assessment.

Limitations

HOMA-Beta is a fasting-model estimate and is affected by assay variability and population differences. It should not be used alone for diagnosis or treatment decisions.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools

Endocrinology

HOMA-IR

Estimate insulin resistance using fasting glucose and fasting insulin with the HOMA-IR equation.

Open Endocrinology

QUICKI

Estimate insulin sensitivity using fasting glucose and fasting insulin with the QUICKI formula.

Open Endocrinology

HbA1c Converter

Convert HbA1c to estimated average glucose (eAG): 6%=126 mg/dL, 7%=154, 8%=183, 9%=212. ADA 2026 target <7% for most adults with diabetes. Shows both mg/dL and mmol/L.

Open

Frequently Asked Questions

HOMA-β (HOMA-%B or HOMA-Beta) is a mathematical model that estimates the functional secretory capacity of pancreatic beta cells under fasting conditions. It was introduced by Matthews et al. in 1985 alongside HOMA-IR as part of the Homeostatic Model Assessment (HOMA) framework. It uses fasting insulin and fasting glucose to estimate what percentage of 'normal' beta-cell function a person retains, expressed as a percentage where 100% represents normal function.

HOMA-β estimates basal insulin secretion — specifically how much insulin the beta cells are producing in the fasting state relative to the prevailing glucose level. It is a proxy for the secretory reserve of the pancreatic beta cells under steady-state fasting conditions. It does not measure first-phase (glucose-stimulated) insulin secretion, which is typically the earliest defect in T2DM development and requires dynamic testing (IVGTT or oral glucose tolerance test).

HOMA-β is expressed as a percentage where 100% represents normal beta-cell function in a healthy non-diabetic adult. Normal range is approximately 80–120%. Values of 40–80% suggest moderate beta-cell decline (typical early T2DM or prediabetes). Below 40% indicates significant beta-cell loss, typical of established T2DM or LADA. Values above 120% reflect compensatory hypersecretion, often seen in insulin-resistant but normoglycemic individuals.

HOMA-IR estimates insulin resistance (how well cells respond to insulin), while HOMA-β estimates beta-cell secretory function (how much insulin the pancreas can produce). They assess complementary aspects of glucose metabolism: HOMA-IR captures peripheral and hepatic sensitivity to insulin; HOMA-β captures the pancreatic secretory side. Both are calculated from the same fasting insulin and glucose values, but using different formulas.

The UKPDS demonstrated that T2DM patients have already lost approximately 50% of their beta-cell function by the time of clinical diagnosis. HOMA-β at T2DM diagnosis typically ranges from 40–60% of normal. Beta-cell function then continues to decline progressively at approximately 4% per year despite treatment, driving the progressive nature of T2DM and the eventual need for insulin therapy in most patients after years of oral medication use.

LADA (Latent Autoimmune Diabetes in Adults) is an autoimmune form of diabetes often misdiagnosed as T2DM. LADA patients characteristically have very low HOMA-β (often below 25–30% within 3–5 years of diagnosis) combined with positive anti-GAD antibodies. Low HOMA-β in a patient thought to have T2DM — especially if lean, young, or poorly controlled on oral agents — should prompt anti-GAD antibody testing to rule out LADA.

Online Medical Tools — HOMA-Beta

HOMA-Beta

How It Works

Enter fasting insulin and glucose

Calculator applies the HOMA-β formula

Interpret the result as a percentage of normal function

Who Uses the HOMA-Beta

Monitoring T2DM Beta-Cell Decline Over Time

LADA Differentiation from T2DM

Assessing GLP-1 Agonist Beta-Cell Effects

Predicting Insulin Requirement in T2DM

New-Onset Diabetes Classification Research

Pro Tips

The HOMA-β formula has a known mathematical limit

T2DM patients have lost ~50% of beta-cell function by diagnosis

Combine HOMA-β with HOMA-IR for full insulin axis picture

GLP-1 agonists appear to improve HOMA-β over time

LADA patients have low HOMA-β and positive anti-GAD antibodies

Early insulin resistance shows paradoxically elevated HOMA-β

Different ethnic groups have different baseline beta-cell capacities

Exogenous insulin users cannot be assessed

Serial measurements are more informative than single values

Common Questions About Your Results

Evidence-Based Methodology

Clinical Content Trust

How to Interpret Your Result

When to Use This Tool

Limitations

Changelog

Related Tools

HOMA-IR

QUICKI

HbA1c Converter

Further Reading

Endocrinology Guide: Diabetes, Thyroid Disorders, and Hormone Management

Frequently Asked Questions